Mark Mitchnick, Red Queen Therapeutics CEO
August 6, 2024 07:00 AM EDT
Financing
Startups
R&D

A new Ap­ple Tree Part­ners biotech launch­es with $55M to make ‘pan-vari­ant’ an­tivi­rals 

Lei Lei Wu

News Reporter

Red Queen Ther­a­peu­tics is emerg­ing from stealth with $55 mil­lion from ven­ture cap­i­tal group Ap­ple Tree Part­ners, and plans to de­vel­op treat­ments for a swathe …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times